3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Carboplatin
9
Pemetrexed
7
osimertinib
5
pembrolizumab
3
entinostat
3
durvalumab
3
Radiosurgery
3
Cisplatin
3
Bevacizumab
3
selpercatinib
2
camrelizumab
2
Paclitaxel
2
Gemcitabine
2
Erlotinib Hydrochloride
2
Docetaxel
2
trametinib
1
sotorasib
1
repotrectinib
1
pralsetinib
1
patritumab
1
nazartinib
1
napabucasin
1
icotinib
1
exemestane
1
cobimetinib
1
ceralasertib
1
cemiplimab
1
capmatinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bronchial Neoplasms
×
exemestane
×
Thoracic
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled